492 related articles for article (PubMed ID: 26740655)
21. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
[TBL] [Abstract][Full Text] [Related]
22. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
23. Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease.
Barry J; Akopian G; Cepeda C; Levine MS
J Neurosci; 2018 May; 38(20):4678-4694. PubMed ID: 29691329
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
25. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.
Naydenov AV; Sepers MD; Swinney K; Raymond LA; Palmiter RD; Stella N
Neurobiol Dis; 2014 Nov; 71():140-50. PubMed ID: 25134728
[TBL] [Abstract][Full Text] [Related]
26. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
[TBL] [Abstract][Full Text] [Related]
27. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.
Cummings DM; Cepeda C; Levine MS
ASN Neuro; 2010 Jun; 2(3):e00036. PubMed ID: 20585470
[TBL] [Abstract][Full Text] [Related]
28. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
Kim W; Seo H
Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
[TBL] [Abstract][Full Text] [Related]
29. Differential changes to D1 and D2 medium spiny neurons in the 12-month-old Q175+/- mouse model of Huntington's Disease.
Goodliffe JW; Song H; Rubakovic A; Chang W; Medalla M; Weaver CM; Luebke JI
PLoS One; 2018; 13(8):e0200626. PubMed ID: 30118496
[TBL] [Abstract][Full Text] [Related]
30. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
Kolodziejczyk K; Raymond LA
Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
[TBL] [Abstract][Full Text] [Related]
31. Cell-Specific Deletion of PGC-1α from Medium Spiny Neurons Causes Transcriptional Alterations and Age-Related Motor Impairment.
McMeekin LJ; Li Y; Fox SN; Rowe GC; Crossman DK; Day JJ; Li Y; Detloff PJ; Cowell RM
J Neurosci; 2018 Mar; 38(13):3273-3286. PubMed ID: 29491012
[TBL] [Abstract][Full Text] [Related]
32. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
Buren C; Parsons MP; Smith-Dijak A; Raymond LA
Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
[TBL] [Abstract][Full Text] [Related]
33. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
34. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
[TBL] [Abstract][Full Text] [Related]
35. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
Milnerwood AJ; Raymond LA
J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
[TBL] [Abstract][Full Text] [Related]
36. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.
Park KH; Lu G; Fan J; Raymond LA; Leavitt BR
J Huntingtons Dis; 2012; 1(1):89-96. PubMed ID: 24353748
[TBL] [Abstract][Full Text] [Related]
37. Structural and functional features of medium spiny neurons in the BACHDΔN17 mouse model of Huntington's Disease.
Goodliffe J; Rubakovic A; Chang W; Pathak D; Luebke J
PLoS One; 2020; 15(6):e0234394. PubMed ID: 32574176
[TBL] [Abstract][Full Text] [Related]
38. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
39. Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.
Martín-Flores N; Pérez-Sisqués L; Creus-Muncunill J; Masana M; Ginés S; Alberch J; Pérez-Navarro E; Malagelada C
Cell Death Dis; 2020 Jul; 11(7):569. PubMed ID: 32732871
[TBL] [Abstract][Full Text] [Related]
40. Axonal ER Ca
Mackay JP; Smith-Dijak AI; Koch ET; Zhang P; Fung E; Nassrallah WB; Buren C; Schmidt M; Hayden MR; Raymond LA
J Neurosci; 2023 May; 43(20):3743-3763. PubMed ID: 36944490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
